ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview

Reuters10-03

ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview

Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by "liberating enzymes from cells" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify (Video Podcast)

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2572523484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-03 04:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572523484","market":"nz","top_or_hot":-1,"title":"ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by \"liberating enzymes from cells\" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify (Video Podcast)</p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-03 04:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by \"liberating enzymes from cells\" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify (Video Podcast)</p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXOZ","symbol_name":"eXoZymes Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDLbmG7Y7:1","article_id":"2572523484","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572523484","pubTimestamp":1759437943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by \"liberating enzymes from cells\" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify . Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EXOZ":"eXoZymes Inc","BK4139":"生物科技"},"translate_title":"ExoZymes首席执行官Michael Heltzen在独家播客采访中揭示了人工智能驱动的酶革命","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXOZ":0.9},"content_text":"ExoZymes CEO Michael Heltzen Unveils AI-Driven Enzyme Revolution in Exclusive Podcast Interview\n    \n\n        Exozymes Inc. CEO Michael Heltzen recently spoke on the Inside Biotech podcast, sharing the company's innovative approach to chemical manufacturing by \"liberating enzymes from cells\" and leveraging AI-powered enzyme evolution. Heltzen highlighted Exozymes' rapid six-week development timelines, their bold IPO strategy amid challenging biotech markets, and the potential for sustainable, scalable enzyme-based production to transform pharmaceuticals and beyond. The interview offers insights into Exozymes' mission, technology, and future vision for synthetic biology. The full podcast episode is available at: SimplecastApple PodcastSpotify (Video Podcast)\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}